{"name":"NRx Pharmaceuticals","slug":"nrx","ticker":"NRXP","exchange":"NASDAQ","domain":"nrxpharma.com","description":"NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato a","hq":"Wilmington, DE","founded":0,"employees":"29","ceo":"Stephen Willard","sector":"CNS / Psychiatry","stockPrice":3.24,"stockChange":0.29,"stockChangePercent":9.83,"marketCap":"$107M","metrics":{"revenue":1225000,"revenueGrowth":0,"grossMargin":58.8,"rdSpend":3777000,"netIncome":-28622000,"cash":7797000,"dividendYield":0,"peRatio":6.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"ZYESAMI patent cliff ($0.00 at risk)","drug":"ZYESAMI","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-01","label":"Aviptadil patent cliff ($0.00 at risk)","drug":"Aviptadil","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-06-29","type":"regulatory","headline":"NRx Pharmaceuticals Receives FDA Fast Track Designation for ZYESAMI","summary":"The FDA granted Fast Track designation to ZYESAMI for the treatment of COVID-19, a move that could expedite the development and review process.","drugName":"ZYESAMI","sentiment":"positive"},{"date":"2022-03-14","type":"deal","headline":"NRx Pharmaceuticals Announces Collaboration with the University of Maryland for ZYESAMI","summary":"NRx Pharmaceuticals partnered with the University of Maryland to conduct a clinical trial for ZYESAMI in patients with COVID-19.","drugName":"ZYESAMI","sentiment":"neutral"},{"date":"2021-12-14","type":"earnings","headline":"NRx Pharmaceuticals Reports Third Quarter 2021 Financial Results","summary":"NRx Pharmaceuticals reported its third-quarter 2021 financial results, which included revenue of $1.4 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"earnings","source":"simplywall.st","summary":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability - simplywall.st","headline":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOOXloOWRZYWlJM0diVDNzclozWm9SblFXXzU0RDI2MTdPVHR2QWxLd0VpNkhfczlqQ1J2cVVyLUxLclVNZGdfU0l4Vk9ITEpsNkNwelJSdGFVTFZlVTNXWUxQRVBlazBNa21fcUQ3MXR3QklrZVNpWElrcm5QalNUeXpGSWlRMnpQQk1MTk44dEJKYWs4QlltZWQtRjBwczJyQS1keE5UTUw4cWJLa0JSZERzaUJEMHJQaTFvSFpPVQ?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"NRx says it can fund operations through 2026 as ketamine review advances - Stock Titan","headline":"NRx says it can fund operations through 2026 as ketamine review advances","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPclhqMV9PQ3pDN2FocWVFRkNTZmhac1NKWlZROUpnc2xfZ190NzcybEhxS3g2dGdnOEh6ZkNUdmhQRGtjdnJUWHkzRTRjR2pZeFU3MW9pLUUyQjIwakVac1E2RmRIcDNlWUpXZFFsakJUUjVxQndkWXpET1F5YlI3blE3c05DUXRveUZkV24ybldzQVpLQ0t5UENBdzZIeDg2dEF2eXNIdWdGeWZUX2RGX3FEZGlKNHM?oc=5","date":"2026-03-19","type":"pipeline","source":"Stock Titan","summary":"NRx Pharma to outline drug pipeline and clinic network progress March 24 - Stock Titan","headline":"NRx Pharma to outline drug pipeline and clinic network progress March 24","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxONzdaX1NIZHVuWjVsbEJwNmI2eXhIeXpuaWUtc0VwaUlZT3h3NFVBdWlmckp1U1ZlTTV3YlhoRjZXSWRYMnhuMEsyX0xaS25WSFdLUlh3R24zSlhBeDU1NjlkNk04azBZWE9HZGN5WHhyam42cU5qOHRuOGgxbnBUNjAxcVZFc0ZYQzlJaFFuVDNMU1dEN19VVDFTT3B1V29kRXNTOV93eThHcjVkT21BbmpuSTVpVGNRNTI5czBoLTZtRHdGb1drSHZR?oc=5","date":"2026-03-16","type":"pipeline","source":"Benzinga","summary":"Why Is NRx Pharma Stock Gaining Monday? - NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga","headline":"Why Is NRx Pharma Stock Gaining Monday? - NRX Pharmaceuticals (NASDAQ:NRXP)","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPQ3loc0liUmczdERPNENkemRkWUNTLWF4cWV5ZmRMRUN0emQ4aWpZdDJrRVYyMk1JRGlNRkpDaWJUY182MktRZVJvaGMyT3paTVljZ2ZKWUVxb0d6d1BKcmtvVXJWRllxSHpvOXdfcFNpMnVYZ00wcFd6dTVSZFE1Qi1vVUw4b2x1WlgwbTJ5aXIyWkRuNlRGQ1R0cDktd1h1aFpxXzN4b2w5VkhGLTkxejJKYUFsdVVIaVdvdkNaOC10RE5CVVR5RmRZTDFBLUFGZ0pHMGhSYmFkU05wODhiWTh3ejZ5WGN0ZEE?oc=5","date":"2026-01-16","type":"pipeline","source":"globenewswire.com","summary":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date - globenewswire.com","headline":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-14","type":"regulatory","source":"globenewswire.com","summary":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval - globenews","headline":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal ","sentiment":"positive"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPV0w1Sk5hbkxyVkNzZ09kYWVHRUZkakw0RldEdDJBVHljU2JRYzB6LW5GX3VQVVhweGtWNzRUNlBBdllWb3ZYWnJPeXdrRlo5UFQ1NFdWeEhtcU01d0tLX0o5aEpuZkVnN3Q0OGhZLTd6Z0dmdEZkLVgtX0cwdVdpVWxSMXozRTNRVHBNNFhxWVhkUFk3N3o2VGExZ3Z1UC1DY0xjaElLQndmVWc3S1ZiU3JGSjQzenV0MHBRQW9aMA?oc=5","date":"2025-12-18","type":"pipeline","source":"investingnews.com","summary":"NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion - investingnews.com","headline":"NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQcnlnN3hNNURWWm1kYlZ0VGNNRS0zQTB2WnFjTFNPMGgybWxDcDV3cUVtaFlYLXVDT2M5MmZXdExlNDJPSFZnUXQ2TmJDZmlUdWh1TXpIMk9HUmVPS29NNTh4WFRfbV9TdkFDV2lOOTA4TE5DamJJcFNRcTZSQXdmcW9kbmRBM2RiVzVtVHF0OUlHU2QwSFQ2a3AtaC1fQzFlVGdKcHJZak5MNlcxWlZnYXEtWFB0b0RWaThKaVZSSEprc3hXVFdndlQ1OC1kbm42ajU0?oc=5","date":"2025-12-18","type":"pipeline","source":"Quiver Quantitative","summary":"NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative","headline":"NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026","sentiment":"neutral"}],"patents":[{"drugName":"ZYESAMI","drugSlug":"aviptadil","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"Aviptadil","drugSlug":"aviptadil","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Johnson & Johnson","Pfizer","Eli Lilly"],"therapeuticFocus":["Central Nervous System (CNS)","Psychiatry"],"financials":{"source":"sec_edgar+yahoo","revenue":1225000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1225000,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2024-12-31"}],"grossProfit":720000,"grossProfitHistory":[{"period":"2025-12-31","value":720000},{"period":"2024-12-31","value":0}],"rdSpend":3777000,"rdSpendHistory":[{"period":"2025-12-31","value":3777000},{"period":"2024-12-31","value":6199000},{"period":"2023-12-31","value":13371000},{"period":"2022-12-31","value":17027000}],"sgaSpend":13061000,"operatingIncome":-16224000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-16224000},{"period":"2024-12-31","value":-18502000},{"period":"2023-12-31","value":-27587000},{"period":"2022-12-31","value":-44335000}],"netIncome":-28622000,"netIncomeHistory":[{"period":"2025-12-31","value":-28622000},{"period":"2024-12-31","value":-25126000},{"period":"2023-12-31","value":-30150000},{"period":"2022-12-31","value":-39754000}],"eps":-2.36,"epsHistory":[{"period":"2024-12-31","value":-2.36},{"period":"2023-12-31","value":-3.98},{"period":"2022-12-31","value":-6.1},{"period":"2021-12-31","value":-74.4}],"cash":7797000,"cashHistory":[{"period":"2025-12-31","value":7797000},{"period":"2024-12-31","value":1443000},{"period":"2023-12-31","value":4595000},{"period":"2022-12-31","value":20054000}],"totalAssets":12956000,"totalLiabilities":28893000,"totalDebt":631000,"equity":-15937000,"operatingCashflow":-14112000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-14112000},{"period":"2024-12-31","value":-10637000},{"period":"2023-12-31","value":-21657000},{"period":"2022-12-31","value":-39755000}],"capex":-3000,"capexHistory":[{"period":"2023-12-31","value":-3000},{"period":"2022-12-31","value":-10000},{"period":"2021-12-31","value":-7000}],"freeCashflow":-14112000,"dividendsPaid":null,"buybacks":null,"employees":29,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4569000,"ebit":1031000,"ebitda":1131000,"period":"2025-12-31","revenue":983000,"epsBasic":null,"netIncome":360000,"rdExpense":558000,"epsDiluted":null,"grossProfit":575000,"operatingIncome":-4624000},{"sga":2808000,"ebit":-5890000,"ebitda":-5847000,"period":"2025-09-30","revenue":242000,"epsBasic":-0.27,"netIncome":-5890000,"rdExpense":1429000,"epsDiluted":-0.27,"grossProfit":145000,"operatingIncome":-4024000},{"sga":2743000,"ebit":-17581000,"ebitda":-17581000,"period":"2025-06-30","revenue":0,"epsBasic":-0.98,"netIncome":-17581000,"rdExpense":987000,"epsDiluted":-0.98,"grossProfit":null,"operatingIncome":-3730000},{"sga":2943000,"ebit":-5512000,"ebitda":-5512000,"period":"2025-03-31","revenue":0,"epsBasic":-0.34,"netIncome":-5512000,"rdExpense":804000,"epsDiluted":-0.34,"grossProfit":null,"operatingIncome":-3747000},{"sga":2598000,"ebit":-9078000,"ebitda":-9077000,"period":"2024-12-31","revenue":0,"epsBasic":null,"netIncome":-9078000,"rdExpense":1036000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-2432000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.15,"netIncome":null,"rdExpense":null,"epsDiluted":-0.15,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.24,"previousClose":2.95,"fiftyTwoWeekHigh":3.84,"fiftyTwoWeekLow":1.62,"fiftyTwoWeekRange":"1.62 - 3.84","fiftyDayAverage":2.42,"twoHundredDayAverage":2.5,"beta":2.02,"enterpriseValue":90286472,"forwardPE":6.5,"priceToBook":-6.44,"priceToSales":87.46,"enterpriseToRevenue":73.7,"enterpriseToEbitda":-5.6,"pegRatio":0,"ebitda":-16118000,"ebitdaMargin":0,"freeCashflow":-805875,"operatingCashflow":-14112000,"totalDebt":631000,"debtToEquity":0,"currentRatio":0.31,"returnOnAssets":-121.8,"returnOnEquity":0,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":38.25,"targetHighPrice":49,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":8.3,"institutionHeldPercent":27.7,"sharesOutstanding":33067630,"floatShares":24244853,"sharesShort":4407012,"shortRatio":4.34,"shortPercentOfFloat":13.3,"epsTrailing":-1.34,"epsForward":0.5,"revenuePerShare":0.06,"bookValue":-0.5,"officers":[{"age":68,"name":"Dr. Jonathan C. Javitt M.D., M.P.H.","title":"Co-Founder, Chairman, CEO & Chief Scientist Officer"},{"age":55,"name":"Mr. Michael S. Abrams M.B.A.","title":"CFO & Treasurer"},{"age":74,"name":"Mr. Joseph M. Casper","title":"Chief Operating Officer"},{"age":63,"name":"Dr. Riccardo  Panicucci Ph.D.","title":"Chief Manufacturing & Technology Officer"},{"age":null,"name":"Suzanne  Messere","title":"Investor Relations"},{"age":78,"name":"Dr. Philip T. Lavin Ph.D.","title":"Chief Methodologist"},{"age":70,"name":"Dr. Dennis K. McBride Ph.D.","title":"Chief Strategy Officer & Director"},{"age":null,"name":"Prof. Joshua C. Brown M.D., Ph.D.","title":"Chief Medical Innovation Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.nrxpharma.com","phone":"484 254 6134"}}